Tenax Therapeutics, Inc. (TENX)

Tenax Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	9.79	2.12	5.58	6.25	4.91
Short-Term Investments	0	0	0	0.46	0.49
Cash & Cash Equivalents	9.79	2.12	5.58	6.71	5.4
Cash Growth	361.09%	-61.97%	-16.82%	24.32%	-58.02%
Other Current Assets	1.89	1.08	0.11	0.08	0.78
Total Current Assets	11.68	3.21	5.69	6.8	6.18
Property, Plant & Equipment	0	0.19	0.29	0.06	0.18
Other Long-Term Assets	0	0.01	0.01	0.01	0.01
Total Long-Term Assets	0	0.2	0.3	0.07	0.18
Total Assets	11.68	3.4	5.99	6.87	6.37
Accounts Payable	2.07	0.45	0.86	0.76	1.66
Current Debt	0.5	0.62	0	0.12	0
Other Current Liabilities	1.01	0.78	0.7	1.24	0.87
Total Current Liabilities	3.59	1.85	1.56	2.12	2.53
Long-Term Debt	0	0.06	0.18	0.12	0.06
Total Long-Term Liabilities	0	0.06	0.18	0.12	0.06
Total Liabilities	3.59	1.91	1.75	2.24	2.59
Total Debt	0.5	0.69	0.18	0.24	0.06
Debt Growth	-27.25%	275.02%	-24.96%	305.20%	-
Retained Earnings	-297.25	-289.54	-278.49	-246.02	-236.17
Comprehensive Income	0	0	0	-0	0
Shareholders' Equity	8.1	1.49	4.24	4.63	3.77
Net Cash / Debt	9.29	1.44	5.4	6.47	5.34
Net Cash / Debt Growth	547.39%	-73.42%	-16.51%	21.14%	-58.49%
Net Cash Per Share	37.40	78.04	419.90	998.34	1379.00
Working Capital	8.1	1.36	4.13	4.68	3.65
Book Value Per Share	32.59	81.17	330.05	713.97	974.26

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).